NIH Reform Act
- Bill Number
- H.R. 1497
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-02-21: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2025-12-05T22:08:33Z
AI-Generated Summary
Purpose of the Legislation
The NIH Reform Act (H.R. 1497) aims to restructure part of the National Institutes of Health (NIH) by dividing the existing National Institute of Allergy and Infectious Diseases (NIAID) into three separate, specialized research institutes. This is intended to allow more focused research, training, and programs on allergic diseases, infectious diseases (including tropical diseases), and immunologic diseases and disorders.
Key Provisions
- Creation of New Institutes:
- Establishes the National Institute of Allergic Diseases, focused on allergic diseases and disorders.
- Establishes the National Institute of Infectious Diseases, focused on infectious diseases, including tropical diseases.
- Establishes the National Institute of Immunologic Diseases, focused on immunologic diseases and disorders.
- Director Appointments: Directors for each new institute are appointed by the President with the advice and consent of the Senate (a confirmation process). Terms are 5 years, with one possible reappointment.
- Transition Process: The current NIAID Director position ends upon enactment. The new institutes are temporarily overseen by the NIH Director until new directors are appointed. Existing authorities and responsibilities related to infectious and immunologic diseases are transferred to the appropriate new institutes.
- Updates to Laws and References: Amends the Public Health Service Act to reflect the changes. All references in U.S. laws, regulations, documents, and records to NIAID are updated to point to the relevant new institute.
Significant Changes to Existing Law
- Structural Reorganization: Amends Section 401 of the Public Health Service Act to add the three new institutes and increase the total number of NIH institutes from 27 to 29. The original NIAID is renamed and limited to allergic diseases only.
- Shift in Responsibilities: Transfers specific duties from NIAID (e.g., research on infectious and immunologic issues) to the new institutes, with new subparts added to the Act for their purposes.
- Appointment Requirements: Introduces Senate confirmation for these directors and sets fixed term limits, differing from some existing NIH director roles.
- Conforming Edits: Removes or updates references to NIAID in other sections of the Public Health Service Act, such as those related to advisory councils and interagency coordination.
Potential Impacts
- On Government Agencies: The NIH will undergo administrative restructuring, potentially increasing specialization in research but also requiring resources for transitions, new leadership, and separate operations. This could affect coordination on overlapping health issues like pandemics.
- On Citizens: Patients and communities affected by allergies, infections, or immune disorders may benefit from more targeted research funding and programs, potentially leading to faster advancements in treatments or prevention.
- On International Relations: Minimal direct impact, though enhanced focus on infectious and tropical diseases could strengthen U.S. contributions to global health efforts, such as vaccine development or outbreak responses.
Main Stakeholders Affected
- NIH and Researchers: Scientists, staff, and grantees in allergy, infectious disease, and immunology fields will need to adapt to new organizational structures and funding streams.
- Patients and Advocacy Groups: Individuals with allergic, infectious, or immunologic conditions, along with related nonprofits, could see shifts in research priorities and support.
- Government Officials: The President (for appointments), Senate (for confirmations), and congressional committees (e.g., Energy and Commerce) will have expanded oversight roles.
- Broader Public Health Community: Healthcare providers, pharmaceutical companies, and international health organizations may experience changes in collaboration and funding opportunities.
Notable Legal, Constitutional, or Political Implications
- Legal: Relies on amendments to the Public Health Service Act (a key law governing federal health research), ensuring continuity of authorities while mandating an orderly transition to avoid disruptions in ongoing programs.
- Constitutional: Involves the President's appointment power under Article II, balanced by Senate confirmation, which upholds the checks-and-balances system without altering core executive authority over agencies.
- Political: As an introduced bill from specific House members, it reflects debates on NIH efficiency and specialization. If enacted, it could spark discussions on federal bureaucracy, research funding allocation, and leadership accountability, potentially influencing future health policy reforms.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (6)
Rep. Griffith, H. Morgan [R-VA-9], Rep. Hageman, Harriet M. [R-WY-At Large], Rep. Crane, Elijah [R-AZ-2], Rep. Brecheen, Josh [R-OK-2], Rep. Harris, Andy [R-MD-1], Rep. Gosar, Paul A. [R-AZ-9]
Recent Actions
- 2025-02-21: Referred to the House Committee on Energy and Commerce.
- 2025-02-21: Introduced in House
- 2025-02-21: Introduced in House
Bill Versions
- NIH Reform Act — issued 2025-02-21 — PDF (8 pages)